Much literature has confirmed that the ER co-activator MED1 often co-amplifies with HER2 in primary breast cancers[26,27] and that HER2 amplification or overexpression can enhance MED1 phosphorylation by activating the MAPK/ERK pathway, thus affecting ER activity[34–36]. This evidence concerns the gene MED1 and breast carcinoma.